AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has recently completed a Phase 2a clinical study titled A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. The study aimed to assess the safety, tolerability, and pharmacokinetic profile of AZD2389, a drug intended to treat liver fibrosis and compensated cirrhosis, compared to a placebo.
The intervention being tested is AZD2389, an oral drug designed to manage liver fibrosis and compensated cirrhosis. The study explored how the body absorbs, distributes, and metabolizes this drug.
The study was interventional, with a randomized, parallel assignment model. It was single-blind, meaning participants and investigators were blinded to the treatment allocation. The primary purpose of the study was treatment-focused.
The study started on December 6, 2024, and the last update was submitted on August 13, 2025. These dates are crucial as they mark the timeline of the study’s progress and completion.
The completion of this study could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence and market position in the competitive pharmaceutical industry. It could also impact competitors working on similar treatments.
The study is completed, and further details are available on the ClinicalTrials portal.